{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T09:58:06Z","timestamp":1793699886070,"version":"4.5.1"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec id=\"ab-yoi230107-4\"><jats:title>Importance<\/jats:title><jats:p>There is growing interest in the role of gut microbiome composition in schizophrenia. However, lifestyle factors are often neglected, and few studies have investigated microbiome composition in treatment-resistant schizophrenia.<\/jats:p><\/jats:sec><jats:sec id=\"ab-yoi230107-5\"><jats:title>Objective<\/jats:title><jats:p>To explore associations between the gut microbiome and schizophrenia diagnosis, treatment resistance, clozapine response, and treatment-related adverse effects while adjusting for demographic and lifestyle factors.<\/jats:p><\/jats:sec><jats:sec id=\"ab-yoi230107-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>In this case-control study of adults aged 20 to 63 years, stool samples and data on demographic characteristics, lifestyle, and medication use were collected and gut microbiome measures obtained using shotgun metagenomics. Participants with a schizophrenia diagnosis were referred through psychiatric inpatient units and outpatient clinics. Data were collected for 4 distinct groups: control individuals without a psychiatric diagnosis (past or present), individuals with treatment-responsive schizophrenia taking nonclozapine antipsychotic medications, clozapine-responsive individuals with treatment-resistant schizophrenia, and clozapine-nonresponsive individuals with treatment-resistant schizophrenia. Participants were recruited between November 2020 and November 2021. Control individuals were recruited in parallel through posters and online advertisements and matched for age, sex, and body mass index (BMI) to the individuals with schizophrenia. Participants were excluded if taking antibiotics in the past 2 months, if unable to communicate in English or otherwise follow study instructions, were pregnant or planning to become pregnant, or had any concomitant disease or condition making them unsuited to the study per investigator assessment. Data were analyzed from January 2022 to March 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-yoi230107-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Omics relationship matrices, \u03b1 and \u03b2 diversity, and relative abundance of microbiome features.<\/jats:p><\/jats:sec><jats:sec id=\"ab-yoi230107-8\"><jats:title>Results<\/jats:title><jats:p>Data were collected for 97 individuals (71 [74%] male; mean [SD] age, 40.4 [10.3] years; mean [SD] BMI, 32.8 [7.4], calculated as weight in kilograms divided by height in meters squared). Significant microbiome associations with schizophrenia were observed at multiple taxonomic and functional levels (eg, common species: <jats:italic>b<\/jats:italic><jats:sup>2<\/jats:sup>, 30%; SE, 13%; adjusted <jats:italic>P<\/jats:italic>\u2009=\u2009.002) and treatment resistance (eg, common species: <jats:italic>b<\/jats:italic><jats:sup>2<\/jats:sup>, 27%; SE, 16%; adjusted <jats:italic>P<\/jats:italic>\u2009=\u2009.03). In contrast, limited evidence was found for microbiome associations with clozapine response, constipation, or metabolic syndrome. Significantly decreased microbial richness was found in individuals with schizophrenia compared to control individuals (t<jats:sub>95<\/jats:sub>\u2009=\u20094.25; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001; mean [SD] for control individuals, 151.8 [32.31]; mean [SD] for individuals with schizophrenia, 117.00 [36.2]; 95% CI, 18.6-51.0), which remained significant after a covariate and multiple comparison correction. However, limited evidence was found for differences in \u03b2 diversity (weighted UniFrac) for schizophrenia diagnosis (permutational multivariate analysis of variance [PERMANOVA]: <jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>, 0.03; <jats:italic>P<\/jats:italic>\u2009=\u2009.02), treatment resistance (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>, 0.02; <jats:italic>P<\/jats:italic>\u2009=\u2009.18), or clozapine response (<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>, 0.04; <jats:italic>P<\/jats:italic>\u2009=\u2009.08). Multiple differentially abundant bacterial species (19) and metabolic pathways (162) were found in individuals with schizophrenia, which were primarily associated with treatment resistance and clozapine exposure.<\/jats:p><\/jats:sec><jats:sec id=\"ab-yoi230107-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings in this study are consistent with the idea that clozapine induces alterations to gut microbiome composition, although the possibility that preexisting microbiome differences contribute to treatment resistance cannot be ruled out. These findings suggest that prior reports of microbiome alterations in individuals with chronic schizophrenia may be due to medication or lifestyle factors and that future studies should incorporate these variables in their design and interpretation.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2023.5371","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:32:58Z","timestamp":1706718778000},"page":"292","source":"Crossref","is-referenced-by-count":41,"title":["Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia"],"prefix":"10.1001","volume":"81","author":[{"given":"Svetlina S.","family":"Vasileva","sequence":"first","affiliation":[{"name":"Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia"},{"name":"Queensland Centre for Mental Health Research, Wacol, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhao","family":"Yang","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia"},{"name":"Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Baker","sequence":"additional","affiliation":[{"name":"Queensland Centre for Mental Health Research, Wacol, Queensland, Australia"},{"name":"Metro South Addiction and Mental Health Service, Metro South Health, Brisbane, Brisbane South, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[{"name":"Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia"},{"name":"Queensland Centre for Mental Health Research, Wacol, Queensland, Australia"},{"name":"Metro South Addiction and Mental Health Service, Metro South Health, Brisbane, Brisbane South, Queensland, Australia"},{"name":"University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Gratten","sequence":"additional","affiliation":[{"name":"Mater Research Institute, University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Eyles","sequence":"additional","affiliation":[{"name":"Queensland Brain Institute, University of Queensland, Brisbane, Queensland, Australia"},{"name":"Queensland Centre for Mental Health Research, Wacol, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"yoi230107r1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis.","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"yoi230107r2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S2215-0366(19)30132-4","article-title":"The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness.","volume":"6","author":"Firth","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"yoi230107r3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1192\/bjp.2021.61","article-title":"Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis.","volume":"220","author":"Siskind","year":"2022","journal-title":"Br J Psychiatry"},{"issue":"5","key":"yoi230107r4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.","volume":"209","author":"Siskind","year":"2016","journal-title":"Br J Psychiatry"},{"issue":"11","key":"yoi230107r5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis.","volume":"62","author":"Siskind","year":"2017","journal-title":"Can J Psychiatry"},{"issue":"1","key":"yoi230107r6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.","volume":"83","author":"De Hert","year":"2006","journal-title":"Schizophr Res"},{"key":"yoi230107r7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-230X-11-17","article-title":"Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.","volume":"11","author":"De Hert","year":"2011","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"yoi230107r8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0920-9964(02)00498-X","article-title":"Obesity as a risk factor for antipsychotic noncompliance.","volume":"66","author":"Weiden","year":"2004","journal-title":"Schizophr Res"},{"issue":"1","key":"yoi230107r9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/ijnp\/pyy067","article-title":"Making sense of \u2026 the microbiome in psychiatry.","volume":"22","author":"Bastiaanssen","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"yoi230107r10","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41467-020-15457-9","article-title":"Metagenome-wide association of gut microbiome features for schizophrenia.","volume":"11","author":"Zhu","year":"2020","journal-title":"Nat Commun"},{"key":"yoi230107r11","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.schres.2017.04.017","article-title":"Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response.","volume":"192","author":"Schwarz","year":"2018","journal-title":"Schizophr Res"},{"issue":"12","key":"yoi230107r12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115225","article-title":"The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse.","volume":"9","author":"Morgan","year":"2014","journal-title":"PLoS One"},{"key":"yoi230107r13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.schres.2018.05.017","article-title":"Changes in metabolism and microbiota after 24-week risperidone treatment in drug naive, normal weight patients with first episode schizophrenia.","volume":"201","author":"Yuan","year":"2018","journal-title":"Schizophr Res"},{"issue":"10","key":"yoi230107r14","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1038\/tp.2013.83","article-title":"Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat.","volume":"3","author":"Davey","year":"2013","journal-title":"Transl Psychiatry"},{"issue":"4","key":"yoi230107r15","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1152\/physrev.00018.2018","article-title":"The microbiota-gut-brain axis.","volume":"99","author":"Cryan","year":"2019","journal-title":"Physiol Rev"},{"issue":"5","key":"yoi230107r16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14740338.2022.2042251","article-title":"Does the gut microbiome mediate antipsychotic-induced metabolic side effects in schizophrenia?","volume":"21","author":"Vasileva","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"yoi230107r17","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/s41591-021-01552-x","article-title":"Reporting guidelines for human microbiome research: the STORMS checklist.","volume":"27","author":"Mirzayi","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"yoi230107r18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/1039856220917080","article-title":"High-dose antipsychotic therapy and reflective prescribing: development of an online tool for rapid, easy calculation of antipsychotic total daily dose.","volume":"28","author":"Northwood","year":"2020","journal-title":"Australas Psychiatry"},{"issue":"9","key":"yoi230107r19","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40263-021-00847-4","article-title":"Absolute and dose-adjusted serum concentrations of clozapine in patients switching vs. maintaining treatment: an observational study of 1979 patients.","volume":"35","author":"Kylles\u00f8","year":"2021","journal-title":"CNS Drugs"},{"issue":"5","key":"yoi230107r20","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/dme.2006.23.issue-5","article-title":"Metabolic syndrome\u2014a new world-wide definition. a consensus statement from the International Diabetes Federation.","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"issue":"8","key":"yoi230107r21","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1007\/s10620-017-4599-6","article-title":"The validity of a new Structured Assessment of Gastrointestinal Symptoms Scale (SAGIS) for evaluating symptoms in the clinical setting.","volume":"62","author":"Koloski","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"1","key":"yoi230107r22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13059-019-1718-z","article-title":"OSCA: a tool for omic-data-based complex trait analysis.","volume":"20","author":"Zhang","year":"2019","journal-title":"Genome Biol"},{"issue":"24","key":"yoi230107r23","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1016\/j.cell.2021.10.015","article-title":"Autism-related dietary preferences mediate autism-gut microbiome associations.","volume":"184","author":"Yap","year":"2021","journal-title":"Cell"},{"issue":"6","key":"yoi230107r25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/ele.2006.9.issue-6","article-title":"Multivariate dispersion as a measure of beta diversity.","volume":"9","author":"Anderson","year":"2006","journal-title":"Ecol Lett"},{"issue":"1","key":"yoi230107r26","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1038\/s41467-020-17041-7","article-title":"Analysis of compositions of microbiomes with bias correction.","volume":"11","author":"Lin","year":"2020","journal-title":"Nat Commun"},{"key":"yoi230107r27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.bbi.2021.09.014","article-title":"Antipsychotic-induced gastrointestinal hypomotility and the alteration in gut microbiota in patients with schizophrenia.","volume":"99","author":"Xu","year":"2022","journal-title":"Brain Behav Immun"},{"issue":"23","key":"yoi230107r28","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.v63.23","article-title":"Abundance of probiotics and butyrate-production microbiome manages constipation via short-chain fatty acids production and hormones secretion.","volume":"63","author":"Zhuang","year":"2019","journal-title":"Mol Nutr Food Res"},{"key":"yoi230107r29","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.777961","article-title":"Gut metagenome as a potential diagnostic and predictive biomarker in slow transit constipation.","volume":"8","author":"Tian","year":"2022","journal-title":"Front Med"},{"key":"yoi230107r30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.schres.2018.01.002","article-title":"Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study.","volume":"197","author":"Shen","year":"2018","journal-title":"Schizophr Res"},{"key":"yoi230107r31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bbi.2019.06.039","article-title":"Altered gut microbiota and mucosal immunity in patients with schizophrenia.","volume":"85","author":"Xu","year":"2020","journal-title":"Brain Behav Immun"},{"key":"yoi230107r32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpsychires.2020.02.005","article-title":"Alteration of the gut microbiome in first-episode drug-na\u00efve and chronic medicated schizophrenia correlate with regional brain volumes.","volume":"123","author":"Ma","year":"2020","journal-title":"J Psychiatr Res"},{"issue":"12","key":"yoi230107r33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1001\/jamapsychiatry.2021.2573","article-title":"Perturbations in gut microbiota composition in psychiatric disorders: a review and meta-analysis.","volume":"78","author":"Nikolova","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"yoi230107r34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/schbul\/sbad049","article-title":"Compositional and functional alterations in intestinal microbiota in patients with psychosis or schizophrenia: a systematic review and meta-analysis.","volume":"49","author":"Murray","year":"2023","journal-title":"Schizophr Bull"},{"key":"yoi230107r24","volume-title":"Wiley StatsRef: Statistics Reference Online 1-15","author":"Anderson","year":"2017"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2814638\/jamapsychiatry_vasileva_2024_oi_230107_1709150820.1051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T16:01:27Z","timestamp":1709740887000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2814638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.5371","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,1]]}}}